The dupletism of unconventional T cells in cancer

Mark Lawrence a,b,1, Robert Wiesheu a,b,1, Seth B. Coffelt a,b,*

a Cancer Research UK Beatson Institute, Glasgow, UK
b Institute of Cancer Sciences, University of Glasgow, UK

ARTICLE INFO

Keywords:
- Unconventional T cells
- Cancer
- Mouse models
- Gamma delta T cells
- MAIT cells
- NKT cells

ABSTRACT

Unconventional T cells and their involvement in cancer are understudied in comparison to conventional T cells, but recent findings indicate that these cells play important roles in both cancer progression and inhibition. Here, we briefly review the dichotomous role of three unconventional T cell lineages: γδ T cells, MAIT cells and NKT cells. Studies using mouse models of cancer show how this unconventional trilogy interacts with cancer epithelial cells and other immune cell populations during tumour evolution. These reports highlight various potential avenues for therapeutic intervention that may be exploited for cancer immunotherapy.

1. Introduction

T cell receptor (TCR)-expressing cells consist of two groups. One group is the well-known conventional T cells that are educated by dendritic cells and recognise processed peptides through major histocompatibility complex (MHC) molecules. The other group is the understudied, enigmatic unconventional T cells that sense a variety of molecules through their TCR, including peptides, lipids, metabolites and surface proteins. In the cancer immunology field, the trilogy of unconventional T cells – γδ T cells, mucosal-associated invariant T (MAIT) cells and natural killer T (NKT) cells – have received far less attention than conventional T cells. However, in recent years, there has been a growing appreciation of the diverse role of unconventional T cells in cancer.

Although these cells express a TCR, their innate-like properties, such as independence of antigen-mediated education via MHC molecules and rapid response to their cytokine milieu, and the plasticity of γδ T cells, MAIT cells and NKT cells, provides these cells with the ability to quickly adapt to their surroundings. But at the same time, these qualities leave them susceptible to manipulation by tumour-derived factors. Here, we briefly review the pro- and anti-tumorigenic role of unconventional T cells in cancer, as well as their potential for therapeutic exploitation. We specifically focus on recent functional data from mouse models. Unconventional T cell evolution, development, tissue-specific niches and function during non-tumour immunity has been reviewed elsewhere (Mayassi, 2021; Pellicci et al., 2020).

2. Pro-tumour functions of unconventional T cells

2.1. Pro-tumour γδ T cells

Among the three types of unconventional T cells with known accessory roles in cancer progression and metastatic dissemination, γδ T cells are the best studied (Silva-Santos et al., 2019). γδ T cells are defined by their unique TCR, which consists of gamma and delta chains that bind CD3 molecules. In mice, γδ T cells mediate many pro-tumour functions through expression of IL-17A, a pleiotropic cytokine that modulates the behaviour of cancer cells, immune cells and stromal cells (Fig. 1A). There are two subsets of γδ T cells expressing different TCRs that primarily produce IL-17A: Vγ4+ and Vγ6+ cells. However, it is unclear whether IL-17A-producing Vγ4+ and Vγ6+ cells have distinct functions or whether their TCR is important for IL-17A production. It is also unclear what their TCRs recognise. In mouse models of Apc-mutant colon cancer, IL-17A-producing γδ T cells encourage early tumour development via direct stimulation of the IL-17 receptor on intestinal epithelial cells, which promotes their proliferation and inhibits their expression of CXCL9 and CXCL10 to prevent anti-tumour CD8+ T cell recruitment (Wang, 2014; Housseau, 2016; Chen, 2019). Within the gut, these IL-17A-producing γδ T cells are activated by microbiome-induced IL-23 resulting from disruption of mucosal barrier by early tumours (Griennikov, 2012). IL-17A-producing γδ T cells are also important in mouse models of breast, liver and ovarian cancers where they re-educate myeloid cells, such as neutrophils and macrophages, towards an
3. Anti-tumour functions of unconventional T cells

3.1. Anti-tumour γδ T cells

γδ T cells were discovered in the 1980s and have been associated with anti-tumour function ever since. In mice, skin-resident γδ T cells expressing the Vγ5 TCR protect against cutaneous tumour development by orchestrating a Type-2 immune response via secretion of IL-13 and B cell immunoglobulin class switching to IgE (Girardi, 2001; 2003; Strid, 2008; Dalessandri, 2016; Crawford, 2018). While epidermal Vγ5+ cells recognise nascent cancer cells via the NKGD2 receptor (Girardi, 2001; Strid, 2008), gut-resident γδ T cells expressing the Vγ7 TCR recognise immunosuppressive and pro-angiogenic phenotype (Rei, 2014; Benevides, 2015; Ma, 2014; Coffelt, 2015; Wellenstein, 2019). In a KRAS mutant, p53-deficient lung cancer model, γδ T cells encourage neutrophil infiltration into lungs to further disease progression (Jin, 2019). Not only do γδ T cells control myeloid cell behaviour, but IL-17A-producing γδ T cells can also respond to signals from neutrophils and macrophages, and these myeloid cells can either promote or inhibit γδ T cell function (Coffelt, 2015; Wellenstein, 2015; Menzurado, 2015). To foster breast cancer metastasis formation, p53-deficient cancer cells release WNT ligands to stimulate IL-17. In tumour-associated macrophages, and IL-17 activates γδ T cells to produce IL-17A (Coffelt, 2015; Wellenstein, 2019). Similarly, IL-17 and IL-23 from myeloid cells can be up-regulated by the lung microbiome to stimulate IL-17A from γδ T cells (Jin, 2019). These data reinforce how crosstalk between γδ T cells, neutrophils and macrophages is important to drive cancer progression. Recent data indicate that ageing favours the expansion of both Vγ4+ and Vγ6+ cells, leading to accelerated tumour growth in transplantable lung cancer models. This expansion occurs in the lymph nodes of old mice by increased expression of IL-7 (but not IL-17 or IL-23), which induces proliferation of IL-17A-producing γδ T cells without affecting their phenotype (Chen, 2019). In addition to IL-17A, γδ T cells can also produce amphiregulin (AREG), a ligand for the epidermal growth factor receptor (EGFR), and IL-22; both of these molecules can stimulate proliferation of cancer cells (Jin, 2019). Pro-tumorigenic γδ T cells in models of pancreatic cancer and fibrosarcoma may express PD-L1, Galectin-1 or Galectin-9 to suppress cytotoxic T cells (Rutkowski, 2015; Daley, 2016). Therefore, the functions of γδ T cell subsets exert their pro-tumorigenic function through a variety of mechanisms.

2.2. Pro-tumour MAIT cells

MAIT cells use their TCR to bind the non-polymorphic MHC class-I related (MR1) receptor on other cells. This interaction dictates the development and function of MAIT cells through binding of microbial metabolites, such as the vitamin B metabolite 5-OP-RU which is expressed on various immune cells. As such, MR1-deficient mice, which lack MAIT cells, can be used to test the importance of these cells in cancer progression. In fact, injection of melanoma cells into the tail vein of Mr1−/− mice or induction of fibrosarcoma by carcinogen injection into Mr1−/− mice exhibit reduced tumour growth when compared to wild-type mice, indicating that MAIT cells promote cancer progression in these models (Yan, 2020). MAIT cells can suppress the activity of NK cells and CD8+ T cells, as shown by a reduction in IFNγ production and the degradation marker, CD107a (Fig. 1B). Similar results have been reported using intravenous inoculation of B16 melanoma cells into B6-MAIT−/− mice, which exhibit greater frequencies of MAIT cells than wild-type C57BL/6 mice due to increased rearrangements of the TCRα (Vα19 Jα33) locus (Cui, 2015). In these experiments with B6-MAIT−/− mice, MAIT cells support tumour growth through dampening NK cell maturation (Petley, 2021). Like γδ T cells, MAIT cells are triggered to express IL-17A (as well as TNF) in these models. There is evidence that MAIT cell-derived IL-17A impacts IFNγ and CD107a expression in NK cells, since adoptive transfer of MAIT cells from Il17a−/− mice into Mr1−/− mice fails to suppress NK cells (Yan, 2020). Together, these data suggest some common functionality between unconventional T cells. However, the activation of IL-17A-producing MAIT cells and γδ T cells may be different, because IL-17A expression in MAIT cells is dependent on MR1-induced TCR stimulation whereas IL-17A expression in γδ T cells is dependent on the cytokines, IL-12 and IL-23.

2.3. Pro-tumour NKT cells

Like MAIT cells, the TCR expressed by NKT cells consists of alpha/beta heterodimers, and their TCR binds lipids presented by CD1d rather than metabolites. NKT cells can also produce IL-17A, but whether these cells use IL-17A to promote cancer progression is unknown. NKT cells consist of at least two subsets that are defined by expression of the Vα14Jα18 invariant Vα TCR. Vα14+Jα18+ NKT cells are capable of inducing a type 2 immune response via secretion of IL-13 and B cell immunoglobulin class switching to IgE (Girardi, 2001; 2003; Strid, 2008; Dalessandri, 2016; Crawford, 2018). While epidermal Vγ5+ cells recognise nascent cancer cells via the NKGD2 receptor (Girardi, 2001; Strid, 2008), gut-resident γδ T cells expressing the Vγ7 TCR recognise
nascen cancer cells through CD103-EpCAM interactions and inhibit their development (Morikawa, 2021). With regards to their TCR, gut resident Vγ7+ cells interact with epithelial-derived BTLN1 and BTLN6, whereas Vγ5+ cells in the skin are shaped by their ligation with SKINT1 (Boyden, 2008; Di Marco Barros, 2016). However, the effects of these interactions in the context of cancer remain unknown. Anti-tumour γδ T cells with the ability to traffic to lymph nodes mainly express Vγ1 and Vγ4 TCRs, and these cells counteract cancer progression in transplantable and spontaneous mouse models of cancer (Lanca, 2013; Liu, 2008; Street, 2004). TCR ligands for these subtypes have yet to be identified. Adoptive transfer of Vγ1+Vγ4+ cells can also delay tumour growth and metastasis through secretion of IFNγ and perforin (Liu, 2008; He, 2010; Beck, 2010). Besides their capability to elicit direct tumour cell lysis, IFNγ-producing γδ T cells can augment anti-tumour CD8+ T cell function and increase cancer cell visibility by upregulating expression of MHC-I molecules (Gao, 2003; Riond, 2009). More recently, γδ T cells were shown to modulate dendritic cell recruitment to gastric tumours via GM-CSF expression, effectively mounting an anti-tumour CD8+ T cell response (Medina, 2019). Another recent study investigated the distinct metabolic landscape of γδ T cell subsets and revealed that glucose supplementation is beneficial specifically for IFNγ-producing anti-tumour γδ T cells. Proof-of-principle experiments show that IFNγ-producing γδ T cells expanded in high glucose medium are more efficient in controlling E0771 mammary tumours than IFNγ-producing γδ T cells expanded with normal glucose levels (Lopes, 2021). These studies indicate that both tissue-resident and circulating γδ T cells may be exploited for cancer immunotherapy (Fig. 1D).

3.2. Anti-tumour MAIT cells

The anti-tumour activity of MAIT cells has been illustrated in two recent studies. These studies show that activation of MAIT cells via TCRα-MR1 interactions using the 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) antigen reduces tumour growth of B16 melanoma and a variety of other transplantable cell lines in syngeneic mice (Petley, 2021; Ruf, 2021). Activation of MAIT cells by 5-OP-RU – delivered directly into mice or presented to cancer cells before injection into mice – seems to provoke anti-tumour responses from MAIT cells (Fig. 1E). These effects are observed in wild-type C57BL/6 mice as well as MAIT cell-rich B6-MAITCAST mice. However, antigen delivery directly to cancer cells does not result in reduced tumour growth for every cell line, since MAIT cells are unable to reduce tumour growth of 5-OP-RU-pulsed E0771 mammary cancer cells in B6-MAITCAST mice. This may be explained by the low expression of MR1 on E0771 cells. In the transplantation models where MAIT cells play an anti-tumour role, the tumour reduction phenotype can be reversed using Mr1−/− mice. These data suggest that host-derived, not cancer cell-derived, MR1, is the crucial mediator driving the anti-tumour functions of MAIT cells. Indeed, CRISPR/CAS9-mediated knockout of Mr1 in B16 melanoma cells has no effect on the ability of MAIT cells to counteract tumour growth in wild-type mice. So how do MR1-associated antigens affect MAIT cells, and how do these cells counteract cancer progression? 5-OP-RU changes the phenotype of MAIT cells by increasing expression of IFNγ, CD69 and the NK cell activation receptor, DNAM-1, while decreasing expression of the inhibitory ligand, CD96. 5-OP-RU-treated mice also exhibit enhanced activation and activity of cytotoxic NK cells, whose depletion abrogates the reduction in tumour growth. Therefore, MAIT cells encourage NK cell-mediated anti-tumour immunity, underscoring their ability to influence other effector populations to inhibit cancer progression (Petley, 2021; Ruf, 2021). There are also discrepancies in the literature that need resolving. For example, in the same B16 melanoma model, MAIT cells can exhibit both pro- and anti-tumour functions (Van, 2020; Petley, 2021; Ruf, 2021). These contradictory observations may be explained by the use of 5-OP-RU-mediated TCR stimulation to skew cells towards an anti-tumour phenotype; although, further work is needed for clarification.

3.3. Anti-tumour NKT cells

Several studies from 10 to 20 years ago have shown that endogenous Type I, Ja18+ NKT cells counteract tumour growth and elicit anti-tumour immunity in transplantable cancer models of melanoma, lung cancer, sarcoma, prostate cancer and lymphoma [reviewed in (Fuji and Shimizu, 2019; Godfrey, 2018)]. In addition, adoptive transfer of NKT cells into B16 melanoma-bearing mice indicates that these cells have potent anti-tumour properties with the ability to control tumour growth (Li, 2019). NKT cells directly kill CD1d+ cancer cells, but they can also enhance anti-tumour γδ T cells and dendritic cells as well as inhibit immunosuppressive neutrophils to prevent cancer progression (Fuji and Shimizu, 2019; Godfrey, 2018). More recent studies have shown that NKT cells protect against tumorigenesis in a spontaneous mouse model of KRAS-driven pancreatic cancer by dampening the pro-tumorigenic functions of macrophages (Janakiram, 2017). NKT cells can even restore the effector functions of exhausted CD8+ T cells after these cells become resistant to anti-PD-1 therapy, by providing cytokines, such as IL-2 and IL-12 (Bae, 2018). Very little information on the mechanisms that regulate NKT cells is known; although, insights have been uncovered in mouse models of primary hepatocellular carcinoma and liver metastasis (Fig. 1F). Antibiotic treatment of these tumour models increases CXCR6-expressing NKT cell numbers and reduces liver tumour growth in a NKT cell-dependent manner (Ma, 2018). Here, the microbiome controls expression of the CXCL16 chemokine, the ligand for CXCR6, in liver sinusoidal endothelial cells via modification of bile acid metabolism. Bile acids recirculate back to the liver from the gut to dampen CXCL16 expression, which prevents expansion of anti-tumour NKT cells. These data suggest that antibiotics may be beneficial for cancer patients with liver tumours.

4. Discussion

Although unconventional T cells have received less attention than conventional T cells for their participation in cancer progression, it is clear from the studies discussed above that these rare cells are crucial players. Going forward, it will be essential to establish the context in which pro- or anti-tumorigenic γδ T cells, MAIT cells and NKT cells are favoured; to determine the cancer types where these cells play a role; and to understand how these cells are regulated in different scenarios, including how genetic mutations and metabolic changes in cancer cells affect presentation of unconventional TCR ligands. The name given to γδ T cells, MAIT cells and NKT cells are de facto umbrella terms to describe a group of cells with similar characteristics, but each population encompasses both pro- and anti-tumorigenic subsets. Thus, it will be important for the research community to move beyond knockout mice that deplete entire populations and to generate specific models for manipulation of specific cell subsets. Data from single-cell RNA sequencing experiments should help further distinguish pro- and anti-tumorigenic subsets and identify similarities (and differences) to their human counterparts. Unconventional T cells in laboratory mice can exhibit differences to the same cell populations in humans, including their relative frequency, amino acid composition of their TCRs as well as their gene expression profile. Additionally, differences in microbiome between laboratory mice and humans will have impact on the development and behaviour of unconventional T cells during cancer progression. These differences must be considered when transferring information on γδ T cells, MAIT cells and NKT cells from mouse models to human cancer. Nevertheless, what is evident from the literature reviewed herein is the importance of crosstalk between unconventional T cells and other immune cell populations. More efforts on uncovering the molecular links between immune cells could open up new immunotherapeutic opportunities for cancer patients. Similarly, boosting the inherent anti-tumour properties of unconventional T cells with new strategies, such as metabolic alterations (Lopes, 2021), will be useful for cell-based therapies, especially in low (neo)antigen-expressing tumours.
where conventional T cells are ineffective.

Financial support
This work was supported by grants from Breast Cancer Now (2019DecPhD1349) and Pancreatic Cancer UK (2017FutureLeaders Academy).

Declarations of interest
None.

References
Ambrosio, E., et al., 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179 (8), 5126–5136.
Bae, E.A., et al., 2018. Activation of NKT cells in an anti-PD-1-resistant tumor model enhances antitumor immunity by reinvestigating exhausted CD8 T cells. Cancer Res. 78 (18), 5315–5326.
Beck, B.H., et al., 2010. Adoptively transferred ex vivo expanded gammadelta T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res. Treat. 122 (1), 135–144.
Benevides, L., et al., 2015. IL17 promotes mammary tumor progression by changing the behavior of tumor cells and eliciting tumorigenic neutrophils recruitment. Cancer Res. 75 (18), 3786–3799.
Boyden, L.M., et al., 2008. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells. Nat. Genet. 40 (5), 656–662.
Chen, C., et al., 2019. IL-7-dependent compositional changes within the gammadelta T cell pool in lymph nodes during age leading to an unbalanced anti-tumor response. EMBO Rep. 20 (8), e47379.
Chen, J., et al., 2019. IL-17 inhibits CXC/9/10-mediated recruitment of CD8+ cytotoxic T cells and regulatory T cells to colorectal tumors. J. Immunother. Cancer 7 (1), 324.
Coffelt, S.B., 2015. IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522 (7556), 345–348.
Crawford, G., 2018. Epithelial damage and tissue gammadelta T cells promote a unique tumor-protective IgE response. Nat. Immunol. 19 (8), 859–870.
Cui, Y., et al., 2015. Mucosal-associated invariant T cell-rich congenic mouse strain where conventional T cells are ineffective. J. Immunother. Cancer 7 (1), 324.
Di Marco Barros, R., et al., 2016. Epithelia use butyrophilin-like molecules to shape organ-specific gammadelta T cell compartments. Cell 167 (1), 203–218 e17.
Fujii, S.I., Shimizu, K., 2019. Immune networks and therapeutic targeting of iNKT cells in breast cancer. Immunity 48 (3), 453–463.
Girardi, M., et al., 2003. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med. 198 (3), 433–442.
Girardi, M., et al., 2001. Regulation of cutaneous malignancy by gammadelta T cells. Science 294 (5542), 605–609.
Girardi, M., et al., 2005. The distinct contributions of murine T cell receptor (TCR) gammadelta and TCRalpha+ T cells to different stages of chemically induced skin cancer. J. Exp. Med. 198 (5), 747–755.
Goffrey, D.J., et al., 2018. Unconventional T cell targets for cancer immunotherapy. Immunity 48 (3), 453–473.
Grivennikov, S.I., et al., 2012. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491 (7423), 254–258.
He, W., et al., 2010. Naturally activated V gamma 4 gamma delta T cells play a protective role in tumor immunity through expression of esomesodomin. J. Immunol. 185 (1), 126–133.
Housseau, F., et al., 2016. Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis. Cancer Res. 76 (8), 2115–2124.
Jankiram, N.B., 2017. Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+ ) mice. Immunology 152 (1), 36–51.
Jin, C., et al., 2019. Commensal microbiota promote lung cancer development via gammadelta T cells. Cell 176 (5), 998–1013 e16.
Lancz, T., et al., 2013. Protective role of the inflammatory CCR2/CL2 chemokine pathway through recruitment of type 1 cytotoxic gammadelta T lymphocytes to tumor beds. J. Immunol. 190 (12), 6673–6680.
Li, Z., 2019. Mouse CD8(-)NKT-like cells exert dual cytotoxicity against mouse tumor cells and myeloid-derived suppressor cells. Cancer Immunol. Immunother. 68 (9), 1303–1315.
Liu, Z., et al., 2008. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J. Immunol. 180 (9), 6044–6053.
Lopes, N., 2021. Distinct metabolic programs established in the thymus control effector functions of gammadelta T cell subsets in tumor microenvironments. Nat. Immunol. 22 (2), 179–192.
Ma, C., 2018. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360 (6391).
Ma, S., 2014. IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Res. 74 (7), 1969–1982.
Mayarsi, T., 2021. A multilayered immune system through the lens of unconventional T cells. Nature 595 (7868), 501–510.
Medina, B.D., 2019. Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity. J. Exp. Med.
Menurardo, S., 2018. Tumor-associated neutrophils suppress pro-tumoral IL-17+ gammadelta T cells through induction of oxidative stress. PLoS Biol. 16 (5), e2004990.
Morikawa, R., 2021. Intraepithelial lymphocytes suppress intestinal tumor growth by cell-to-cell contact via CD103/E-Cadherin signal. Cell Mol. Gastroenterol. Hepatol. 11 (5), 1485–1503.
Pellicci, D.G., Kozy, H.F., Berzins, S.P., 2020. Thymic development of unconventional T cells: how NKT cells, MAIT cells and gammadelta T cells emerge. Nat. Rev. Immunol.
Petley, E.V., et al., 2021. MAIT cells regulate NK cell-mediated tumor immunity. Nat. Commun. 12 (1), 4746.
Rei, M., et al., 2014. Murine CD27(+)/Vgamma6(+) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages. Proc. Natl. Acad. Sci. USA 111 (34), E3562–E3570.
Riond, J., et al., 2009. In vivo major histocompatibility complex class I (MHC) expression on MHCIIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun. 9, 10.
Ruf, B., et al., 2021. Activating mucosal-associated invariant T cells induces a broad antitumor response. Cancer Res. 79 (9), 1024–1034.
Rutkowski, M.R., 2015. Microbially driven TLRs-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27 (1), 27–40.
Silva-Santos, B., Menurardo, S., Coffelt, S.B., 2019. gammadelta T cells: pleiotropic immune effectors with therapeutic potential in cancer. Nat. Rev. Cancer 19 (7), 392–404.
Street, S.E., 2004. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199 (6), 879–884.
Strids, J., et al., 2008. Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat. Immunol. 9 (2), 146–154.
Terabe, M., 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and IL-4/STAT6 pathway. Nat. Immunol. 1 (6), 515–520.
Terabe, M., 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198 (11), 1741–1752.
Terabe, M., et al., 2005. A nonclassical non-Valpha14Ialpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J. Exp. Med. 202 (12), 1627–1633.
Wang, K., et al., 2014. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41 (6), 1052–1063.
Wang, Y., et al., 2018. Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells. Mucosal Immunol. 11 (1), 131–143.
Wellenstein, M.D., et al., 2019. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature 572 (7770), 538–542.
Yan, J., et al., 2020. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. 10 (1), 124–141.